Parizac

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Parizac

What is Parizac?

Parizac is a pharmaceutical medication classified as a selective serotonin reuptake inhibitor (SSRI). It contains the active ingredient fluoxetine and is primarily used in the management of various mental health conditions, including clinical depression, certain anxiety-related disorders, and obsessive-compulsive patterns.

How Parizac Works

The medication functions by influencing the chemical environment of the brain. It specifically targets serotonin, a neurotransmitter responsible for transmitting signals between nerve cells. Serotonin is known to play a significant role in regulating mood, sleep, and emotional stability.

In individuals with certain mood or anxiety disorders, serotonin levels may be imbalanced or the signals may be inefficiently transmitted. Parizac works by inhibiting the reabsorption (reuptake) of serotonin into the neurons. This process increases the availability of serotonin in the synaptic gap between cells, which helps to strengthen the transmission of nerve impulses and can lead to an improvement in mood and emotional regulation.

Therapeutic Applications

Parizac is utilized to address several distinct psychological conditions:

  • Major Depressive Disorder: It helps alleviate persistent feelings of sadness, loss of interest, and the low energy levels associated with clinical depression.
  • Obsessive-Compulsive Disorder (OCD): It is used to help reduce the frequency and intensity of intrusive thoughts and repetitive behaviors.
  • Panic Disorder: The medication can help decrease the occurrence of sudden, intense episodes of fear and the physical symptoms that accompany them.
  • Bulimia Nervosa: It is sometimes used as part of a comprehensive program to reduce the cycle of binge-eating and purging behaviors.

Parizac is designed to be a long-term stabilization tool rather than an immediate relief medication, as the adjustment of neurotransmitter levels typically occurs gradually over several weeks.

Regulatory References

  1. Omeprazole: MedlinePlus Drug Information

What side effects are possible with Parizac?

Parizac (Omeprazole) is a Proton Pump Inhibitor whose safety profile is officially classified by regulatory authorities based on the frequency and type of documented adverse reactions. These reactions are categorized into System-Organ Classes (SOCs) covering various bodily systems, including gastrointestinal, nervous system, and musculoskeletal.

Frequency-Classified Adverse Reactions

The official labeling defines several tiers of adverse reactions by incidence:

  • Common Reactions: These are reactions reported with the highest frequency and typically involve the nervous system (e.g., headache) and the gastrointestinal system (e.g., abdominal pain, diarrhea, constipation, flatulence, nausea, and vomiting).
  • Uncommon Reactions: These include effects such as insomnia, dizziness, increased liver enzymes, rash, and malaise.
  • Rare and Very Rare Reactions: These categories include less frequent but clinically significant events such as hypersensitivity reactions (e.g., angioedema, anaphylactic shock), hyponatremia, interstitial nephritis, hepatitis, and severe cutaneous reactions like Stevens-Johnson Syndrome (SJS).

Safety Considerations Based on Exposure and Population

The regulatory safety documents outline specific considerations related to treatment duration and certain patient populations. Prolonged use (typically one year or more) is officially associated with an increased risk of bone fractures (hip, wrist, or spine) and deficiencies, including hypomagnesemia and Vitamin B12 deficiency. Furthermore, the label notes that patients with severe hepatic impairment may be at higher risk for certain adverse events, and geriatric use carries specific warnings regarding fracture risk. Omeprazole can also interfere with certain diagnostic tests, such as Chromogranin A (CgA) for neuroendocrine tumors, which is a documented safety constraint.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Omeprazole documents that overexposure may result in a variety of transient clinical manifestations. These officially described presentations include central nervous system effects such as confusion and drowsiness, as well as autonomic and visual changes like blurred vision, flushing, headache, and diaphoresis (increased sweating). Gastrointestinal and cardiovascular symptoms such as nausea, vomiting, dry mouth, and tachycardia (increased heart rate) have also been reported. Official regulatory statements confirm that no serious clinical outcome has been documented following overdosage with Omeprazole alone.

In the event of an overdose, official guidance dictates that the individual must seek immediate medical attention or contact a Poison Control Center right away. Treatment is officially designated as symptomatic and supportive because no specific antidote for omeprazole overdosage is known. Due to its extensive protein binding, the compound is noted to be not readily dialyzable. Contacting emergency services is required if severe signs like seizure or collapse are present.

Therapeutic Uses of Parizac

Quick Facts on Parizac’s Uses

  • Addresses: Symptoms of gastroesophageal reflux disease (GERD), including frequent heartburn.
  • Helps Manage: Conditions where the stomach produces excess acid, such as Zollinger-Ellison syndrome.
  • Assists in the Healing of: Damage to the esophagus caused by GERD (erosive esophagitis).
  • Supports: The management and healing of ulcers in the stomach or intestine.
  • Used in Combination to: Reduce the recurrence of ulcers linked to H. pylori bacteria.

Parizac (Omeprazole) is indicated for addressing several conditions related to the overproduction of stomach acid. Its primary use is in the management of gastroesophageal reflux disease (GERD) by helping to control symptoms like heartburn and acid regurgitation.

In individuals with acid-related damage to the esophagus, Parizac is used to promote healing of the tissue. It is also a treatment option for both benign stomach (gastric) and intestinal (duodenal) ulcers. When ulcers are caused by Helicobacter pylori (H. pylori) infection, Parizac may be combined with other medications to support the reduction of this bacteria and to help decrease the possibility of the ulcers returning.

Additionally, the medication is suitable for longer-term management of conditions where the stomach secretes very high levels of acid, such as Zollinger-Ellison syndrome. The therapeutic goal is to diminish the effect of excess gastric acid and provide relief from related discomfort.

Regulatory References

  1. NIH MedlinePlus omeprazole guidance

Eligibility and Restrictions for Use

Parizac (Omeprazole) eligibility is defined by official regulatory criteria, detailing which populations are permitted to use the medicine and which are restricted or excluded.

Absolute Non-Eligibility

Parizac is contraindicated and must not be used in patients with a known hypersensitivity to omeprazole, substituted benzimidazoles, or any of the product’s excipients. The medicine is also prohibited for individuals concurrently receiving the antiretroviral drugs nelfinavir or rilpivirine-containing products, as this is an absolute contraindication specified in the regulatory label.

Age-Group and Organ Function Rules

Adults are generally eligible for all approved indications. Pediatric eligibility is restricted by minimum age: use is approved starting at ge 1 month of age for Erosive Esophagitis, but use in infants under 1 month of age is officially not established for safety and effectiveness. Patients with hepatic impairment or renal impairment are designated as a Specific Population within regulatory documents, indicating that their use requires special consideration or monitoring.

Conditional Use

Use is classified as conditional for pregnant and lactating individuals. Regulatory labeling requires a clinical risk assessment before use, noting that omeprazole can pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify interactions with Parizac (Omeprazole) primarily based on two mechanisms: its effect on gastric acidity and its influence on hepatic enzyme activity.

Parizac significantly reduces stomach acid, which can decrease the absorption and effectiveness of co-administered drugs that rely on an acidic environment. For this reason, the use of Parizac is officially not recommended with certain antiretroviral medicines, including Atazanavir, Nelfinavir, and Rilpivirine.

Parizac is an inhibitor of the enzyme Cytochrome P450 2C19 ( CYP2C19). This inhibition can increase the systemic exposure of other medicines metabolized by this pathway, such as Cilostazol and Diazepam, potentially requiring monitoring. Conversely, co-administration with strong inducers of CYP2C19 and CYP3A4, such as Rifampin or St. John’s Wort, can reduce Parizac's concentration.

A significant interaction is the diminished anti-platelet effect of Clopidogrel when used concomitantly with Parizac, a combination officially advised to be avoided. Additionally, Parizac use may affect diagnostic test results, such as increasing levels of Chromogranin A ( CgA), which requires temporary cessation prior to testing.

Mechanism of Action

Mechanism of Action: How Parizac Works

Dual Inhibition of Serotonin and Norepinephrine Transporters

Parizac's primary mechanism involves the simultaneous inhibition of the Serotonin Transporter ( SERT) and the Norepinephrine Transporter ( NET). This molecular action directly prevents the reuptake of Serotonin and Norepinephrine from the synaptic cleft, which increases the concentration and duration of these neurotransmitters available for postsynaptic signaling .

Cascade of Neural Adaptation

The persistent elevation of Serotonin and Norepinephrine signaling initiates a sequential mechanistic cascade involving changes in the nerve cell. This cascade leads to the adaptive restructuring and functional regulation of receptors and neural circuits over time. This process ultimately results in changes in receptor density and synaptic function within the affected neural circuits.

Effect on Descending Monoaminergic Pathways

The increased monoamine levels influence the activity of descending regulatory pathways in the central nervous system that modulate sensory input. This modulation adjusts the transmission dynamics within these specific pathways, affecting the flow of information through the central nervous system.

Dosage and Administration Information

Official Administration Guidelines

Parizac (Omeprazole) is a medication administered orally in the form of delayed-release capsules, tablets, or oral suspension powder. The administration protocol is defined to ensure the active ingredient is protected from stomach acid until it reaches the small intestine for absorption.


Dosing and Scheduling

Adult Indication Standard Daily Dose Course Duration (Typical)
Active Gastric Ulcer 40 mg once daily 4 to 8 weeks
Active Duodenal Ulcer 20 mg once daily 4 to 8 weeks
Pathological Hypersecretory Conditions (e.g., ZES) Initial dose is 60 mg once daily Long-term, as clinically needed

For conditions requiring high doses, such as Zollinger-Ellison Syndrome, daily dosages exceeding 80 mg must be administered in divided doses. The medication is generally taken once daily, preferably before a meal. In H. pylori eradication regimens, Parizac is used twice daily in combination with antibiotics.


Procedural Instructions

  • Swallowing: Delayed-release capsules and tablets must be swallowed whole with a liquid. They must not be crushed, chewed, or split, as this compromises the enteric coating designed for proper absorption.
  • Alternative Use: If an intact capsule cannot be swallowed, the contents (pellets) may be opened and mixed with a small amount of a slightly acidic soft food, such as applesauce, and swallowed immediately without chewing the pellets.
  • Missed Dose: If a dose is missed, take it as soon as possible. If it is nearly time for the next scheduled dose, the missed dose should be skipped; do not take two doses at the same time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Parizac

The research base for Omeprazole (Parizac) has been studied across multiple clinical trials and scientific literature. The evidence is derived from studies that evaluate the medicine in specific clinical situations related to measurements related to gastric acid. This overview summarizes the structure of this research, what the studies focused on, and where evidence limitations exist, based on regulatory scientific reviews.


Evidence for Symptomatic Gastroesophageal Reflux Disease (GERD)

Research has primarily used short-term, randomized controlled trials (RCTs) to explore how symptoms change over time when using Omeprazole. These studies were designed to evaluate the short-term symptom patterns in adults and children with GERD, often comparing the medication against an inactive placebo or other acid-reducing compounds.

The trials monitored outcomes related to physical discomfort, such as the frequency and severity of heartburn and acid regurgitation. Findings describe patterns observed in the studies related to changes in reported symptoms during the defined observation periods. Research provides limited context for what happens after the medication is stopped, and long-term patterns of symptom change are not well characterized by the existing randomized evidence.


Evidence for Healing and Maintenance of Esophageal Tissue

A significant body of evidence from multiple short-term RCTs was evaluated in patients with conditions linked to inflammatory states. Studies explored outcomes related to mucosal integrity, using endoscopy as the primary measurement tool. The findings described changes measured in the endoscopic healing rate after treatment periods spanning several weeks.

For those who achieved healing, subsequent long-term RCTs were used in research to assess the outcomes related to the integrity of the healed tissue. These studies monitored the relapse rate (the recurrence of erosions or symptoms) and the durability of the mucosal integrity over follow-up durations, typically up to 12 months.


Evidence for Managing Ulcers and extitH. pylori Infection

Research has explored Omeprazole's use as part of combination therapy with antibiotics. Studies examined the success of eradicating the bacteria. The main outcome monitored was the H. pylori eradication rate, and research explored the subsequent changes in ulcer recurrence. Research noted that the eradication rate was related to the specific combination of antibiotics used.


Research Gaps and Areas of Uncertainty

The evidence base contributes to the broader understanding of acid-related conditions but has documented gaps. Research highlights what is still uncertain regarding very long-term outcomes (beyond one year). While studies describe patterns, the evidence quality varies across studies, particularly for very rare conditions or non-core indications. Consequently, the research provides context but not individual predictions.

Key Studies & References

  1. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184) - NICE Guideline
  2. Omeprazole: a review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs - NCBI Bookshelf/Review

Frequently Asked Questions (FAQ)

Common questions about Parizac (FAQ)


Q: How quickly does Parizac start to work for most people?

A: The initial acid-reducing effect of Parizac is reported in official documents to begin within one hour of taking a dose. The maximum acid-reducing effect typically occurs within two hours. For consistent symptom relief, the full acid suppression effect of consistent daily dosing is typically observed within four days. For over-the-counter uses for frequent heartburn, relief may begin in 1 to 4 days.


Q: Can Parizac be used for anxiety as well as depression?

A: Parizac (Omeprazole) is classified as a Proton Pump Inhibitor (PPI), and its official approved uses relate exclusively to the suppression of gastric acid. These approved indications include conditions like reflux disease and ulcers. According to regulatory documents, Parizac is not indicated for the treatment of mental health conditions such as anxiety or depression.


Q: Does Parizac cause weight gain or weight loss?

A: Weight changes are not listed among the commonly reported side effects in the official product information. The most frequent adverse events described in regulatory safety documents primarily involve the nervous system (like headache) and the gastrointestinal system (such as diarrhea and abdominal pain).


Q: Do I need to take Parizac with food?

A: Official administration guidelines indicate the medicine is generally taken once daily, preferably before a meal. For nonprescription products, it is usually advised in labeling to take the tablet or capsule in the morning, at least one hour before eating.


Q: How does Parizac interact with birth control pills?

A: Official regulatory documents do not specifically list hormonal contraceptives, such as birth control pills, as medicines that require dose adjustment or avoidance due to an interaction with Parizac. Parizac is not documented in official sources as significantly reducing the effectiveness of these contraceptives.


Q: Are there different strengths or forms of Parizac available?

A: Yes, Parizac (Omeprazole) is available in several forms, including delayed-release capsules, delayed-release tablets, and granules that can be mixed into an oral suspension. Official documents note that the available strengths commonly include 10 mg, 20 mg, and 40 mg dosages, among others, depending on the specific product.


Q: Are there any laboratory tests required before starting Parizac?

A: The official labeling does not typically mandate specific lab tests before beginning a standard short course of treatment. However, if Parizac is used long-term (generally one year or more), regulatory documents note an association with potential deficiencies, such as low Vitamin B12 or magnesium, which may warrant monitoring.


Q: Can Parizac be taken with other mental health medications?

A: Parizac can interact with certain medicines processed by a specific liver enzyme called CYP2C19. Regulatory information notes that this can include some mental health medications, such as Diazepam. This means there is a potential for increased levels of these co-administered drugs, which is described in regulatory interaction profiles.


Q: How is Parizac different from other similar medications?

A: Parizac (Omeprazole) is recognized in official literature as the first drug introduced in the Proton Pump Inhibitor (PPI) class. While all PPIs share the fundamental ability to suppress gastric acid, they may differ in how the body processes them (their metabolism pathways) and their specific regulatory-approved indications.


Q: Is Parizac available as a generic medicine?

A: Yes, the active ingredient in Parizac is Omeprazole, and it is available in both brand-name and generic forms. Official drug approval records confirm the availability of generic versions of the medicine.


Q: What is the difference between Parizac and the generic version?

A: Generic Omeprazole is required by regulatory agencies to contain the same active ingredient, strength, and dosage form as the brand-name product. Generic versions must meet official standards, including demonstrating bioequivalence, which means they are expected to act the same way in the body as the brand-name medicine.


Q: Does Parizac affect blood pressure?

A: Changes in blood pressure are not typically listed among the common adverse events of Omeprazole in official regulatory summaries. The most frequently reported side effects are concentrated in the nervous system and gastrointestinal systems.


Q: Can Parizac affect sleep patterns?

A: Yes, according to official safety documents, insomnia (difficulty sleeping) is listed as an uncommon (less frequent) side effect associated with the use of Omeprazole.


Q: What common supplements might interact with Parizac?

A: Official documents note that the herbal supplement St. John’s Wort can reduce the concentration of Parizac in the body by speeding up certain liver enzymes. Separately, the long-term use of Parizac is officially associated with deficiencies that may require supplementation, such as with Vitamin B12.


Q: Are there genetic factors that affect how Parizac works for a person?

A: Parizac is processed primarily by the CYP2C19 liver enzyme. Official documents on its pharmacology note that differences in how individuals process this enzyme can affect the level of the drug in the body, which is a key concept in pharmacogenetics.


Q: Why is Parizac sometimes prescribed for uses other than depression?

A: Parizac is a Proton Pump Inhibitor, and its official uses are defined by its ability to suppress gastric acid. These approved uses include treating Gastroesophageal Reflux Disease (GERD), healing damage from esophagitis, managing certain ulcers, and addressing conditions involving excessive acid production.


Q: How is the benefit of Parizac measured in clinical studies?

A: Clinical studies officially measure the benefit of Parizac through various means, including the degree of gastric acid suppression achieved and the rate of healing of damaged tissue, such as erosions in the esophagus. Outcomes are also assessed based on changes in reported symptoms, like the frequency and severity of heartburn.


Q: Does Parizac change how other prescribed medications work?

A: Yes, Parizac is documented to potentially change the effect of other prescribed medications through two main mechanisms. It significantly reduces stomach acid, which can reduce the absorption of some drugs that need an acidic environment, and it can inhibit a specific liver enzyme (CYP2C19) used to process other medications.


Q: Can Parizac cause changes in appetite?

A: Changes in appetite are not typically listed among the common adverse events of Omeprazole in official regulatory summaries. The official safety data primarily lists gastrointestinal issues like nausea and abdominal pain as the most frequent side effects.


Q: Does Parizac cause sexual side effects?

A: Sexual side effects are not listed among the common or uncommon adverse reactions in official product labeling. Regulatory documents, however, include rare reports of gynecomastia (enlargement of breast tissue in males) associated with the medicine.


Q: Can Parizac affect my ability to drive or operate machinery?

A: While Parizac is not expected to directly impair a person's ability to drive or use complex machinery, adverse reactions such as dizziness or visual disturbances may occur in some users. If these effects are experienced, regulatory documents state that individuals should avoid driving or operating machinery.


Q: Is Parizac considered a controlled substance?

A: No, Parizac (Omeprazole) is classified as a Proton Pump Inhibitor. It is not listed as a controlled substance under the U.S. Drug Enforcement Administration (DEA) or other major international controlled substance schedules.


Q: Does Parizac interact with cold or flu medicines?

A: Official documents do not specifically highlight significant interactions with common over-the-counter cold or flu ingredients, such as basic pain relievers or decongestants. However, any medicine processed by the CYP2C19 liver enzyme could have a theoretical interaction.


Q: Are there any known serious interactions with over-the-counter pain relievers and Parizac?

A: The official interaction profile primarily highlights specific antiretroviral or antiplatelet medications. Official regulatory documents do not list common over-the-counter pain relievers, such as Acetaminophen or Ibuprofen, as medicines with which Parizac has a major interaction that requires avoidance or dose change.


Q: Does Parizac have a withdrawal syndrome if stopped suddenly?

A: Abrupt discontinuation of Parizac, particularly after long-term use, may lead to a temporary effect known as rebound acid hypersecretion. This can cause the return or worsening of acid-related symptoms, and official patient counseling advises that individuals consult with a healthcare provider before stopping treatment.

How should Parizac be stored and disposed of?

How to Store and Dispose of Parizac (Omeprazole)

Parizac (Omeprazole) must be stored under specific conditions to maintain the stability of its delayed-release formulation, and disposal must follow regulatory guidelines.


Storage Requirements

Condition Regulatory Rule
Temperature Store at controlled room temperature (20 C to 25 C), with excursions up to 30 C.
Protection Must be protected from light and moisture.
Container Keep in the original container or blister packaging and keep the container tightly closed.
Child Safety Store out of the sight and reach of children.

Disposal Instructions

Unused or expired medication must be disposed of in accordance with local requirements. The product should not be flushed down the toilet or poured down a sink. Disposal is generally recommended through a drug take-back program or authorized collection site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Parizac found in:

A-Z Index: